The Royal Marsden NHS Foundation Trust
Welcome,         Profile    Billing    Logout  
 28 Trials 
38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Banerjee, Susana
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
ATARI, NCT04065269: ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Recruiting
2
174
Europe, Canada
Ceralasertib, AZD6738, Olaparib, Durvalumab, MEDI4736
Institute of Cancer Research, United Kingdom, Cancer Research UK, AstraZeneca
Gynaecological Cancers
04/26
04/26
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
12/26
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
SOPRANO, NCT05990192: SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Recruiting
2
42
Europe
Niraparib oral capsule, Zejula, SBRT, Stereotactic Body Radiotherapy
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust
Ovarian Cancer Recurrent
06/27
06/27
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
FRAME, NCT03875820: Phase I Trial of Defactinib and VS-6766.

Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Sep 2020 - Sep 2020: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Checkmark Data from FRAME trial in combination with VS-6766 for solid tumors at AACR 2020
More
Active, not recruiting
1
87
Europe
VS-6766, RO5126766, CH5126766, Defactinib, VS-6063
Institute of Cancer Research, United Kingdom, Verastem, Inc.
NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
04/23
10/23
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
11/24
11/24
NXP800-101, NCT05226507: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

Recruiting
1
61
Europe, US
NXP800
Nuvectis Pharma, Inc., European Network for Gynaecological Oncological Trial Groups, Gynecologic Oncology Group Foundation
Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
05/25
12/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
FAIR-O, NCT04300699: Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian Cancer

Not yet recruiting
N/A
120
NA
Functional Geriatric Assessment
Royal Marsden NHS Foundation Trust
Ovarian Cancer, Chemotherapy, Quality of Life, Tolerance, Aged
12/21
12/22
MONITOR-UK, NCT04295577: Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

Recruiting
N/A
350
Europe
Niraparib
Royal Marsden NHS Foundation Trust
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
02/24
02/24
BriTROC-2, NCT05537844: Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma

Recruiting
N/A
250
Europe
Liz-Anne Lewsley, Ovarian Cancer Action
Ovarian Cancer, High Grade Serous Carcinoma, Carcinosarcoma, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, BRCA1 Mutation, BRCA2 Mutation
10/24
04/25
Bono, Johann De
PROfound, NCT02987543 / 2016-000300-28: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer ( Study)

Checkmark Quality of life data from PROfound trial in mCRPC
Feb 2022 - Feb 2022: Quality of life data from PROfound trial in mCRPC
Checkmark Acceptance of regulatory submission in China for prostate cancer (based on PROfound trial)
Jun 2021 - Jun 2021: Acceptance of regulatory submission in China for prostate cancer (based on PROfound trial)
Checkmark Approved for BRCAm mCRPC with distant metastasis based on PROfound trial
More
Completed
3
387
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, enzalutamide, XTANDI, abiraterone acetate, ZYTIGA
AstraZeneca, Merck Sharp & Dohme LLC, Foundation Medicine, Inc., Myriad Genetics, Inc.
Metastatic Castration-resistant Prostate Cancer
06/19
02/23
PERSEUS1, NCT03506997 / 2017-000931-15: Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

Recruiting
2
100
Europe
Pembrolizumab, Keytruda; MK-3475
Institute of Cancer Research, United Kingdom, Merck Sharp & Dohme LLC
Castration-resistant Prostate Cancer
09/23
09/25
LORIKEET, NCT05848011: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
154
Europe, US, RoW
lorigerlimab, MGD019, docetaxel, Taxotere®, Prednisone
MacroGenics
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
09/26
09/27
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Active, not recruiting
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
02/25
NCT03177187 / 2016-003141-28: Combination Study of AZD5069 and Enzalutamide.

Terminated
1/2
30
Europe
AZD5069, Enzalutamide 40 MG, Xtandi
Institute of Cancer Research, United Kingdom, Astellas Pharma Inc, AstraZeneca, Prostate Cancer UK
Metastatic Castration Resistant Prostate Cancer
09/22
11/22
ACTIon, NCT04458311: Abiraterone Acetate in Combination With Tildrakizumab

Terminated
1/2
13
Europe
Abiraterone Acetate, Yonsa, Tildrakizumab
Institute of Cancer Research, United Kingdom, Sun Pharmaceutical Industries Limited
Metastatic Castration Resistant Prostate Cancer
04/23
11/23
NCT06126731: Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Recruiting
1/2
39
Europe
Enzalutamide 40mg, Xtandi, Amoxicillin 500mg, Metronidazole 400mg, Vancomycin 125mg, Ciprofloxacin 500g
Institute of Cancer Research, United Kingdom, Prostate Cancer Foundation
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
06/24
07/25
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
12/24
12/24
EVICTION, NCT04243499 / 2019-003847-31: First-in-Human Study of ICT01 in Patients With Advanced Cancer

Checkmark Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022
Sep 2022 - Sep 2022: Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022
Recruiting
1/2
150
Europe, US
IV ICT01
ImCheck Therapeutics, ImCheck Therapeutics, Inc.
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
06/25
12/25
CURATE, NCT05272709: TT-702 in Patients With Advanced Solid Tumours.

Recruiting
1/2
188
Europe
TT-702, Darolutamide
Cancer Research UK, Teon Therapeutics, Inc.
Advanced Solid Tumors
06/27
06/27
CRUKD/22/002, NCT05057013: A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Recruiting
1/2
81
Europe
HMBD-001, HMBD-001 and enzalutamide
Cancer Research UK, Hummingbird Bioscience
Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer, RAS Wild Type Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Oesophageal Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Cancer of the Head and Neck
09/26
09/26
ONCT-534-101, NCT05917470: A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Terminated
1/2
21
Europe, US
ONCT-534, GTx-534, UT-34
Oncternal Therapeutics, Inc
Metastatic Castration-resistant Prostate Cancer
09/24
09/24
NCT00516373: A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Checkmark The first set of clinical trials based on inhibiting PARP using olaparib
Nov 2015 - Nov 2015: The first set of clinical trials based on inhibiting PARP using olaparib
Completed
1
98
Europe
KU-0059436 (AZD2281)(PARP inhibitor), Olaparib
AstraZeneca
Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein
12/08
04/23
NCT00516724: Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Checkmark ESMO-ECCO-ESTRO 2013
Sep 2013 - Sep 2013: ESMO-ECCO-ESTRO 2013
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
189
Europe
KU-0059436 (AZD2281)(PARP inhibitor), Olaparib, Carboplatin, CBDCA, Paraplatin®, Paclitaxel, Paclitaxel + Carboplatin
AstraZeneca
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel
01/13
04/24
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
161
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/26
01/26
POTENTIA, NCT04839991: Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

Recruiting
1
70
Europe, US
CB307
Crescendo Biologics Ltd.
Advanced and/or Metastatic Solid Tumours
07/24
09/24
NCT06458712: Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants with Advanced Malignancies

Recruiting
1
90
Europe
DSB2455
Duke Street Bio Ltd
Advanced Malignancies with Homologous Recombination Deficiency (HRD) (Breast, Ovarian, MCRPC, Brain Metastases)
08/27
08/28
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
MAESTRO, NCT03934164: Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) -

Recruiting
N/A
600
Europe
Institute of Cancer Research, United Kingdom, Prostate Cancer UK
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
03/24
03/25
Burrows, Chloe
NCT04659252: CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19)

Recruiting
N/A
70
Europe
n/a - samples collected along routine care samples only
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust
Multiple Myeloma
12/21
12/21
DISCO, NCT05968417: Myeloma Novel Drug Discovery Ver 1.2

Recruiting
N/A
250
Europe
Observational study - sample collection only.
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust
Multiple Myeloma
02/33
02/35
Pawlyn, Charlotte
DISCO, NCT05968417: Myeloma Novel Drug Discovery Ver 1.2

Recruiting
N/A
250
Europe
Observational study - sample collection only.
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust
Multiple Myeloma
02/33
02/35

Download Options